v1
Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro
- NobleID
- NI3P33W46R47S25
- Persistent link
- https://nobleid.org/ark:/48914/w1/20260418/89D3DB17
Type:Journal Article
0 views
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims